Next Article in Journal
Lung Cancer Susceptibility and hOGG1 Ser326Cys Polymorphism: A Meta-Analysis
Next Article in Special Issue
Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology
Previous Article in Journal / Special Issue
CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
Open AccessReview

Mucins and Pancreatic Cancer

INSERM, U837, Jean-Pierre Aubert Research Center, Team 5 "Mucins, epithelial differentiation and carcinogenesis", Lille, France
Author to whom correspondence should be addressed.
Cancers 2010, 2(4), 1794-1812;
Received: 17 September 2010 / Revised: 14 October 2010 / Accepted: 18 October 2010 / Published: 25 October 2010
(This article belongs to the Special Issue Pancreatic Cancer)
Pancreatic cancer is characterized by an often dramatic outcome (five year survival < 5%) related to a late diagnosis and a lack of efficient therapy. Therefore, clinicians desperately need new biomarkers and new therapeutic tools to develop new efficient therapies. Mucins belong to an ever increasing family of O-glycoproteins. Secreted mucins are the main component of mucus protecting the epithelia whereas membrane-bound mucins are thought to play important biological roles in cell-cell and cell-matrix interactions, in cell signaling and in modulating biological properties of cancer cells. In this review, we will focus on the altered expression pattern of mucins in pancreatic cancer, from the early neoplastic lesion Pancreatic Intraepithelial Neoplasia (PanIN) to invasive pancreatic carcinomas, and the molecular mechanisms (including genetic and epigenetic regulation) and signaling pathways known to control their expression. Moreover, we will discuss the recent advances about the biology of both secreted and membrane-bound mucins and their key roles in pancreatic carcinogenesis and resistance to therapy. Finally, we will discuss exciting opportunities that mucins offer as potential therapeutic targets in pancreatic cancer. View Full-Text
Keywords: pancreatic cancer; mucin; regulation; biomarker; therapy pancreatic cancer; mucin; regulation; biomarker; therapy
Show Figures

Figure 1

MDPI and ACS Style

Jonckheere, N.; Skrypek, N.; Van Seuningen, I. Mucins and Pancreatic Cancer. Cancers 2010, 2, 1794-1812.

AMA Style

Jonckheere N, Skrypek N, Van Seuningen I. Mucins and Pancreatic Cancer. Cancers. 2010; 2(4):1794-1812.

Chicago/Turabian Style

Jonckheere, Nicolas; Skrypek, Nicolas; Van Seuningen, Isabelle. 2010. "Mucins and Pancreatic Cancer" Cancers 2, no. 4: 1794-1812.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop